Exclusive Journals Coverage

Exclusive Journals Coverage articles provide quick insight and additional author perspectives on select studies recently published in Journal of Clinical Oncology and Journal of Oncology Practice.

Jun 30, 2014
The study showed it was possible to successfully link a statewide registry that collects data on surgical quality with the tumor registries of 10 hospitals. The database created from the linkage will serve as a platform for a quality assessment program for rectal cancer surgery. 
Jun 23, 2014
The study found that among patients with non-metastatic colorectal cancer, those who consumed more calcium and milk after their diagnosis had a lower rate of death from all causes. These same benefits were not seen in those who consumed more vitamin D . . .
Jun 02, 2014
“For one patient, a 2 or 3% absolute benefit in terms of recurrence rate may be important enough that she would choose to take chemotherapy with all of its various side effects. And for another patient, that same exact amount of benefit is not enough to warrant taking chemotherapy."
May 31, 2014
Watch an exclusive video of Dr. Hudis delivering his Presidential Address at the 50th Meeting of the American Society of Clinical Oncology. The complete transcript is also included.
May 27, 2014
The findings? At the four- to six-month point, women who had received chemotherapy showed significantly decreased brain activity while completing the multitask exercise . . .
May 12, 2014
The study utilized the new technology to assess the clinical value of a panel that honed in on 42 potentially actionable genes among women at high risk for breast cancer who were BRCA negative. It is one of the first studies to focus specifically on patients. . .
May 07, 2014
“Among the patients identified as high-risk based on Padua score, around 20% did not receive thromboprophylaxis,” said Dr. Zwicker. “And in patients identified as low-risk, two-thirds did receive thromboprophylaxis.” This high rate of thromboprophylaxis among low-risk patients is . . .
Apr 28, 2014
The study—in which the CNS stimulant modafinil was given to patients with cancer-related fatigue (CRF)— showed the drug to have no benefit over placebo, although interestingly, both treatments brought about clinically significant changes in CRF. 

Pages